Health · Pharma & Biotech · 21 hrs ago
Novartis returns Lamprene to the US market
Novartis has returned Lamprene to the US market in the United States.
The drug is an antibiotic.
The company received supplemental FDA approval over the summer.
The approval is linked to Lamprene’s return, but no further details about it are given.
The return puts the drug back on the US market.
No further next steps are described.
Novartis has returned its antibiotic Lamprene to the US market.
The company received supplemental approval from the US Food and Drug Administration for the drug over the summer.
The article describes the approval as having been obtained quietly.
The article does not state when Lamprene became available again or why it was returned.
- Who
- Novartis.
- What
- The company returned Lamprene, an antibiotic, to the US market after receiving supplemental FDA approval.
- When
- The supplemental FDA approval was obtained over the summer; the return date is not stated.
- Where
- The United States.
- Why
- Not stated.
This story does not have two clearly opposing sides.
Novartis obtained supplemental FDA approval for Lamprene.
Endpoints News reported that Novartis had returned Lamprene to the US market.
- Company
- Novartis
- Drug
- Lamprene
- Drug type
- Antibiotic
- Market
- United States
- Approval
- Supplemental FDA approval obtained over the summer